UNCY — Unicycive Therapeutics Share News
0.000.00%
Last trade - 00:00HealthcareSmall Cap
Brief: Unicycive Therapeutics Q3 EPS USD -0.13
Brief: Unicycive Therapeutics Reaches Alignment with the FDA on Path to File New Drug Application for Oxylanthanum Carbonate
Brief: Unicycive Therapeutics Received A Notice From Nasdaq That Co Is Not In Compliance With $1.00 Minimum Bid Price Requirement
Brief: Unicycive Therapeutics, Inc. posts Q2 EPS USD -0.29
Brief: Unicycive Therapeutics Says On July 25, Got Notice From Nasdaq, Regained Compliance With Minimum Market Value Requirement For Continued Listing
Brief: RA Capital Management L.P. Reports 9.99% Passive Stake In Unicycive Therapeutics As Of June 26
U.S. RESEARCH ROUNDUP-ACM Research, Constellation Brands, SBA Communications
Brief: Unicycive Therapeutics Provides Regulatory Update On Lanthanum Dioxycarbonate Program
Brief: Unicycive Therapeutics Receives Notice Of Delisting Or Failure From Nasdaq
Brief: Unicycive Therapeutics Enters Into Amendment No. 1 To Securities Purchase Agreement
Brief: Unicycive Announces Full Year 2022 Financial Results And Provides Business Update
Brief: Unicycive Therapeutics Inc - On February 1, 2023, Nasdaq Notified The Company That It Had Not Regained Compliance With The Minimum Bid Price Rule
U.S. STOCKS ON THE MOVE-CrowdStrike, Dentsply Sirona, Qualtrics
U.S. STOCKS ON THE MOVE-Tesla, BridgeBio, Unicycive Therapeutics, Allbirds
Unicycive Therapeutics surges on securing $130 mln financing
U.S. STOCKS ON THE MOVE-Apple, TCR2 Therapeutics, Silvergate Capital
Brief: Unicycive Enters Into Licensing Agreement With Lotus For Renazorb In Korea
Brief: Unicycive Announces Acceptance Of Four Abstracts For Presentation At The World Congress Of Nephrology 2023
Brief: Unicycive Achieves Primary Endpoint In Pivotal Bioequivalence Study Of Renazorb